AB0723 SMOKING MAY BE RELATED TO SACROILIITIS IN ENTEROPATHIC ARTHRITIS PATIENTS: TREASURE REAL-LIFE PRELIMINARY DATA
Authors: Orhan Küçükşahin, Abdulsamet Erden, Ufuk İlgen, Sedat Kiraz, Ali İhsan Ertenli, Nazife Sule Yasar Bilge, Timuçin Kaşifoğlu, Ediz Dalkılıç, Cemal Bes, Nilüfer alpay Kanıtez, Hakan Emmungil, Pamir Atagündüz, Belkis Nihan Seniz, Burcu Yağız, Süleyman Serdar Koca, Muhammet Çınar, Aşkın Ateş, Servet Akar, Önay Gerçik, Duygu Ersözlü, Veli Yazısız, Gezmiş Kimyon, Müge Aydın, Rıdvan Mercan, Burak Öz, Zeynel abidin Akar, Omer Karadag, Bahar Keleşoğlu, Sedat Yılmaz, Yavuz Pehlivan, Ender Terzioğlu, Levent Kılıç, Sukran Erten, Koray Taşçılar, Umut Kalyoncu
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Articular manifestations may differ in ulcerative colitis (UC) and Crohn's disease (CD). Genetic and non-genetic factors like sex, smoking, and presence of HLA-B27 were previously shown to modify the expression of articular and other extraintestinal manifestations of IBD. <h3>Objectives:</h3> The aim of this study is to document disease features and factors affecting the expression of articular manifestations in Turkish patients with IBD-related (enteropathic) arthritis under treatment with disease modifying antirheumatic drugs (DMARDs). <h3>Methods:</h3> Data regarding enteropathic arthritis (EA) were collected from the TReasure database, a nation-wide multicenter observational registry of inflammatory arthritis patients. <h3>Results:</h3> Among 4066 patients with seronegative spondyloarthropaties (SpA), 156 (3.8%) had EA, not reflecting a true prevalence due to selection bias. Demographic and clinical features according to IBD groups were summarized in Table 1. Rates of presence of sacroiliitis were similar between patients with UC and CD (39.9% and 60.1%, p=0.086 respectively). Rates of HLA-B27 positivity were 31.6% and 7.1% in patients with and without radiographic sacroiliitis, respectively (p=0.101). Enthesitis, dactylitis, psoriasis, family history forSpA, ESR, CRP, BASDAI and aSDAS levels had similar distributions in patients with and without radiographic sacroiliitis. Rates of "never-smoked" (26.5% vs 64.7%) and "current smoking" (32.4% vs 17.6%) significantly differed in patients with and without sacroiliitis (overall p=0.012) <h3>Conclusion:</h3> Our data confirm an association between smoking status and disease manifestations, particularly radiographic sacroiliitis. <h3>References</h3> [1] Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol2009; 15: 2449-2455. <h3>Disclosure of interests:</h3> Orhan Küçükşahin: None declared, abdulsamet Erden: None declared, Ufuk İlgen: None declared, Sedat Kiraz: None declared, ali İhsan Ertenli: None declared, Nazife Sule Yasar Bilge: None declared, Timuçin Kaşifoğlu: None declared, Ediz Dalkılıç Grant/research support from: MSD and abbvie, Consultant for: MSD, abbvie,Roche, UCB, Pfizer and Novartis, Speakers bureau: MSD, abbvie,Roche, UCB, Pfizer and Novartis, Cemal Bes: None declared, Nilüfer alpay Kanıtez: None declared, Hakan Emmungil Grant/research support from: MSD, Roche, Pfizer, abbvie, Consultant for: Novartis, Roche, Speakers bureau: MSD, Roche, Pfizer, abbvie,Celltrion, Novartis, Pamir atagündüz: None declared, Belkis Nihan Seniz: None declared, Burcu Yağız: None declared, Süleyman Serdar Koca: None declared, Muhammet Çınar: None declared, aşkın ateş: None declared, Servet akar Grant/research support from: MSD, abbvie, Roche, UCB, Novartis, Pfizer, amgen, Consultant for: MSD, abbvie, Roche, UCB, Novartis, Pfizer, amgen, Speakers bureau: Pfizer, Önay Gerçik: None declared, Duygu Ersözlü: None declared, Veli yazısız: None declared, Gezmiş Kimyon: None declared, Müge aydın: None declared, Rıdvan Mercan: None declared, Burak Öz: None declared, Zeynel abidin akar: None declared, Omer Karadag: None declared, Bahar Keleşoğlu: None declared, Sedat Yılmaz: None declared, Yavuz Pehlivan: None declared, Ender Terzioğlu: None declared, Levent Kılıç: None declared, Sukran Erten: None declared, Koray Taşçılar: None declared, Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer, Consultant for: MSD, abbvie, Roche, UCB, Novartis, Pfizer and abdi Ibrahim, Speakers bureau: MSD, abbvie, Roche, UCB, Novartis, Pfizer and abdi Ibrahim